Hattie Hayes

At ARVO 2025, Mark Bullimore, MCOptom, PhD, emphasized the need for more accurate, condition-specific tools in evaluating myopic eye growth and treatment efficacy.

Lindsell discusses promising retinal therapeutics, such as at-home therapies, gene therapy, and devices like the Valeda Light Delivery System (LumiThera), which uses photobiomodulation and shows early promise in preventing geographic atrophy altogether.

Shamie encourages taking a contemporary, elevated approach to refractive surgery.

Selina McGee, OD, FAAO, emphasized that today’s approach to presbyopia correction must move beyond traditional methods like spectacles and contact lenses.

Hammond and his team focused on creating a reliable conversion factor between 2 widely used optical coherence tomography (OCT) systems—the TopCon Maestro2 and the ZEISS Cirrus 5000. Their work specifically looked at ganglion cell–inner plexiform layer and retinal nerve fiber layer thickness measurements, which are critical markers in glaucoma diagnosis and monitoring.

Dilsher Dhoot, MD, FASRS, shares his forward-looking perspective on developments in retinal disease management, highlighting both recent breakthroughs and promising innovations on the horizon.

As a retinal expert, Ferrucci discusses some emerging retinal therapies that excite him.

At Controversies in Modern Eye Care, Dr McGee talks about helping patients and clinicians expand their understanding of oculoplastics.

An emerging treatment approach for a commonly underdiagnosed ocular surface disease.

At ASCRS 2025, Alex Hacopian, MD, shares information from his presentation on next-gen presbyopia-correcting intraocular lenses.

Eva Kim, MD, offers valuable insights into why EVO ICL is becoming a compelling alternative to traditional corneal procedures like LASIK.

According to a press release, Myatro XL is the first 0.05% atropine eye drop for pediatric myopia control. It will be commercially available in India in July 2025.

The FDA did not agree with a supplemental Biologics License Application for the addition of extended dosing intervals of up to 24 weeks across currently-approved indications.

Nordic Pharma plans to announce commercialization details in the near future for the dry eye disease treatment.

A pivotal phase 3 clinical trial found that SYD-101 met its 3-year primary end point for slowing pediatric myopia progression.

ENCELTO is the first and only FDA-approved treatment for MacTel.

The gel addresses necrotic retinal cell death in dry age-related macular degeneration and geographic atrophy without requiring injections.

Predictive software will use retinal imaging to identify patient risk for Alzheimer disease and other neurodegenerative diseases.

Trending topics and milestone stories from our year in ophthalmology.

New long-term findings illuminate the future of DIMS spectacle lenses.

The FDA comments in the CRL relate to proposed labelling language, not safety, Astellas said in a press release.

The Finnish company's new device sports a universal adapter and rebound tonometry technology.

The RayOne Galaxy and Galaxy Toric IOL will launch at this year's ESCRS Congress in Barcelona, Spain.

Aflibercept-jbvf and aflibercept-yszy are the first interchangeable biosimilars to aflibercept 2 mg that have been approved in the US.

David A. Berntsen, OD, PhD, FAAO, talks through his 2024 ARVO presentation on the BLINK2 study and the findings on axial growth after discontinuing soft multifocal contact lens wear.

Before the ASCRS 2024 meeting, TheiaNova CEO Carissa Fonseca, PhD, pitched a novel keratoconus treatment.